Jan Davidson

Jan Davidson

Company: Macrogenics

Job title: Director of Clinical Development & Research


Flotetuzumab: An Experimental CD123 x CD3 Bispecific DART Molecule for the Treatment of AML 4:05 pm

Clinical study design: Dose and schedule optimization to mitigate cytokine release and deliver target dose Pharmacokinetics & pharmacodynamic: Correlation with designed mechanism of action Biomarker analysis: Identification of primary refractory and early relapse patients as a responsive populationRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.